Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

State Funding Changes in Spotlight in U.S. Republican Healthcare Bill

Susan Heavey & Yasmeen Abutaleb  |  September 22, 2017

WASHINGTON (Reuters)—Republican leaders sought to nail down the final votes needed to pass what U.S. Vice President Mike Pence on Thursday called their “last best chance” to repeal Obamacare while a new analysis underscored how Democratic-leaning states stand to lose large amounts of federal funding under the legislation. Senate Majority Leader Mitch McConnell (R-Ky.) plans…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)Graham-Cassidy AmendmentHealth InsuranceObamacare repealObamacare repeal legislation

Rheumatoid Arthritis Treatments Show Mixed Results

Thomas R. Collins  |  September 19, 2017

MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX) and compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). The drug missed its primary endpoint…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Annual European Congress of Rheumatologyanti-IL6ClinicalDisease-modifying antirheumatic drugs (DMARDs)drugEULARMedicationMethotrexatenanobodyoutcomeRheumatoid arthritisrheumatologistrheumatologyTreatmentvobarilizumab

When Is a Doctor Too Old to Practice?

Simon M. Helfgott, MD  |  September 18, 2017

Steady hands, nerves of steel: The endoscopic transphenoidal hypophysectomy is a delicate neurosurgical procedure. Using a three-dimensional microscope and a powerful magnetic resonance imaging machine to guide them, the surgeon must meticulously dissect the throat tissues, navigate through the palate and the sinuses to reach the base of the skull where the pea-sized master gland,…

Filed under:OpinionRheuminationsSpeak Out RheumWorkforce Tagged with:agingCareerclinicianpatient carephysicianPractice Managementretirementrheumatologistrheumatologywork-life balance

Costly Drugs to Weigh on U.S. Employers’ Expenses in 2018

Divya Grover  |  September 18, 2017

(Reuters)—U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases, such as cancer, multiple sclerosis and hepatitis C, is expected to rise more than 7%, according to consultancy firm Mercer.1 Between 40 and 50 new specialty drugs are set to hit the market each year in…

Filed under:Drug Updates Tagged with:costsemployer-based health insuranceHealth Insurance

Autoantibodies in Autoimmune Myopathy

Autoantibodies in Autoimmune Myopathy

Ruth Jessen Hickman, MD  |  September 18, 2017

In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

Filed under:ConditionsMyositisOther Rheumatic ConditionsResearch Rheum Tagged with:autoantibodiesAutoimmune diseaseClassificationconnective tissue diseasedermatomyositisDiagnosisidiopathic inflammatory myopathiesmyositispatient carepolymyositisprognosisResearchrheumatologistrheumatologySystemic sclerosisTestTreatment

Lymphoma Risk in RA Patients Remains Steady

Kurt Ullman  |  September 17, 2017

Patients with a diagnosis of rheumatoid arthritis (RA) experience on average double the risk of developing malignant lymphoma when compared with the general population. With the major changes in RA treatment taking place over the past decade, has there been a reduction in the risk of lymphoma in this population? Researchers from the Karolinska Institute…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:ACR Journal ReviewAmerican College of Rheumatology (ACR)ClinicalDisease-modifying antirheumatic drugs (DMARDs)lymphomamalignancyMedicationoutcomepatient careregistryResearchRheumatoid arthritisriskSwedish Rheumatology QualityTreatmentTumor Necrosis Factor–Alpha Inhibitor

Prosecutors Identify Insys Founder as Unindicted Co-conspirator in Opioid Case

Nate Raymond  |  September 14, 2017

BOSTON (Reuters)—U.S. prosecutors have identified Insys Therapeutics Inc’s billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document. John Kapoor, who stepped down as chief executive of Insys in January, was…

Filed under:Legal Updates Tagged with:Insys Therapeutics IncJohn Kapooropioid crisisopioid drug companiesOpioid drugmaker probe

Doctors Who Take Pharmaceutical Money Use Twitter to Hype Drugs

Ronnie Cohen  |  September 12, 2017

(Reuters Health)—Some cancer doctors use Twitter to promote drugs manufactured by companies that pay them, but they almost never disclose their conflicts of interest on the social media platform, a new study shows. “This is a big problem,” says senior author Dr. Vinay Prasad, a professor at Oregon Health and Science University in Portland. “Doctors…

Filed under:AppsTechnologyTechnology Tagged with:Conflict of interestSocial MediaTwitter

U.S. Senator Reveals Results of Opioid Inquiry into Insys

Nate Raymond  |  September 7, 2017

BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…

Filed under:Drug UpdatesLegal Updates Tagged with:Insys Therapeutics Incopioid crisisSubsys opioid drugU.S. Democratic Senator Claire McCaskillU.S. Senate report

Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme

Nate Raymond  |  August 31, 2017

(Reuters)—Arizona’s attorney general sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine. The lawsuit by Arizona Attorney General Mark Brnovich in Maricopa County Superior Court in Phoenix comes during a series of federal and state investigations centered on…

Filed under:Drug UpdatesLegal Updates Tagged with:Arizona Attorney General Mark Brnovichfraudulent marketing schemeInsys Therapeutics Inclawsuitopioid crisisSubsys opioid drug

  • « Previous Page
  • 1
  • …
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • 83
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences